Antisense regulation of expression and transactivation functions of the tumorigenic HBx and c-myc genes

Biochemical and Biophysical Research Communications

Volumn 344, Issue 1, 2006, Pages 293-299

  Hung, Le ^a   Kumar, Vijay ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Antisense; Bicistronic; c Myc; CAT assay; Hepatocellular carcinoma; Transactivation; X protein

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE RECOMBINANT AS1; ANTISENSE RECOMBINANT AS2; ANTISENSE RECOMBINANT AS3; ANTISENSE RECOMBINANT AS4; ANTISENSE RECOMBINANT AS5; ANTISENSE RECOMBINANT AS6; COMPLEMENTARY DNA; HEPATITIS B VIRUS X PROTEIN; MYC PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DRUG POTENCY; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC RECOMBINATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; ONCOGENE C MYC; PRIORITY JOURNAL; TRANSACTIVATION; TRANSGENE; TUMOR CELL LINE; VIRUS GENE;

CARCINOMA, HEPATOCELLULAR; DNA, ANTISENSE; DNA, RECOMBINANT; GENE EXPRESSION; GENE THERAPY; GENES, MYC; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

HEPATITIS B VIRUS; MUS MUSCULUS;

EID: 33646052005     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.103     Document Type: Article

References (34)

1. Storz G., Altuvia S., and Wassarman K.M. An abundance of RNA regulators. Annu. Rev. Biochem. 74 (2005) 199-217
2. van der Krol A.R., Mol J.N., and Stuitje A.R. Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. Biotechniques 6 (1988) 958-976
3. Wagner E.G., and Simons R.W. Antisense RNA control in bacteria, phages, and plasmids. Annu. Rev. Microbiol. 48 (1994) 713-742
4. Spencer C.A., Gietz R.D., and Hodgetts R.B. Overlapping transcription units in the dopa decarboxylase region of Drosophila. Nature 322 (1986) 279-281
5. Heywood S.M. tcRNA as a naturally occurring antisense RNA in eukaryotes. Nucleic Acids Res. 14 (1986) 6771-6772
6. Farnham P.J., Abrams J.M., and Schimke R.T. Opposite-strand RNAs from the 5′ flanking region of the mouse dihydrofolate reductase gene. Proc. Natl. Acad. Sci. USA 82 (1985) 3978-3982
7. S. Katayama, Y. Tomaru, T. Kasukawa, K. Waki, M. Nakanishi, M. Nakamura, H. Nishida, C.C. Yap, M. Suzuki, J. Kawai, H. Suzuki, P. Carninci, Y. Hayashizaki, C. Wells, M. Frith, T. Ravasi, K.C. Pang, J. Hallinan, J. Mattick, D.A. Hume, L. Lipovich, S. Batalov, P.G. Engstrom, Y. Mizuno, M.A. Faghihi, A. Sandelin, A.M. Chalk, S. Mottagui-Tabar, Z. Liang, B. Lenhard, C. Wahlestedt, RIKEN Genome Exploration Research Group; Genome Science Group (Genome Network Project Core Group); FANTOM Consortium. Antisense transcription in the mammalian transcriptome. Science 309 (2005) 1564-1566.
8. Yelin R., Dahary D., Sorek R., Levanon E.Y., Goldstein O., Shoshan A., Diber A., Biton S., Tamir Y., Khosravi R., Nemzer S., Pinner E., Walach S., Bernstein J., Savitsky K., and Rotman G. Widespread occurrence of antisense transcription in the human genome. Nat. Biotechnol. 21 (2003) 379-386
9. Scherer L.J., and Rossi J.J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 21 (2003) 1457-1465
10. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270 (2003) 1628-1644
11. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat. Rev. Cancer 5 (2005) 468-479
12. Tamm I., Dorken B., and Hartmann G. Antisense therapy in oncology: new hope for an old idea?. Lancet 358 (2001) 489-497
13. V. Kumar, M. Singh, S.M. Totey, R.K. Anand, Bicistronic DNA construct comprising X-myc transgene for use in production of transgenic animal model systems for human hepatocellular carcinoma and transgenic animal model systems so produced, US Patent No. 6,274,788 B1, 2001.
14. Lakhtakia R., Kumar V., Reddi H., Mathur M., Dattagupta S., and Panda S.K. Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: a sequential pathological evaluation. J. Gastroenterol. Hepatol. 18 (2003) 80-91
15. Kumar V., Jayasuryan N., and Kumar R. A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc. Natl. Acad. Sci. USA 93 (1996) 5647-5652
16. Hung L., and Kumar V. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. FEBS Lett. 560 (2004) 210-214
17. Gorman C.M., Merlino G.T., Willingham M.C., Pastan I., and Howard B.H. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc. Natl. Acad. Sci. USA 79 (1982) 6777-6781
18. Sambrook J., and Russell D.W. Molecular Cloning: A laboratory Manual. third ed. (2001), Cold Spring Harbor Laboratory, New York
19. Doyle K. Protocols and Application Guide (1996), Promega Corporation, Wisconsin
20. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., and Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21 (2003) 635-637
21. Semizarov D., Frost L., Sarthy A., Kroeger P., Halbert D.N., and Fesik S.W. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA 100 (2003) 6347-6352
22. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5 (2003) 834-839
23. Pebernard S., and Iggo R.D. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72 (2004) 103-111
24. Kumar V., and Sarkar D.P. Hepatitis B Virus X protein (HBx): structure-function relationships and role in viral pathogenesis. In: Triezenberg S.J., Kaufman J., and Gossen M. (Eds). Handbook of Experimental Pharmacology vol. 166 (2004), Springer Verlag, Germany 377-407
25. Feitelson M.A. c-myc overexpression in hepatocarcinogenesis. Hum. Pathol. 35 (2004) 1299-1302
26. Garte S.J. The c-myc oncogene in tumor progression. Crit. Rev. Oncog. 4 (1993) 435-449
27. Terradillos O., Billet O., Renard C.A., Levy R., Molina T., Briand P., and Buendia M.A. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14 (1997) 395-404
28. Wu G.Y., and Wu C.H. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267 (1992) 12436-12439
29. Offensperger W.B., Offensperger S., Walter E., Teubner K., Igloi G., Blum H.E., and Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 12 (1993) 1257-1262
30. Korba B.E., and Gerin J.L. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res. 28 (1995) 225-242
31. Nakazono K., Ito Y., Wu C.H., and Wu G.Y. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 23 (1996) 1297-1303
32. Moriya K., Matsukura M., Kurokawa K., and Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem. Biophys. Res. Commun. 218 (1996) 217-223
33. Crooke S.T. Progress in antisense technology. Annu. Rev. Med. 55 (2004) 61-95
34. Coppelli F.M., and Grandis J.R. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr. Pharm. Des. 11 (2005) 2825-2840